• Home
  • ABOUT
    • Our Team
  • Science
    • Programs
    • Our Science
    • Publications
  • Events and Presentations
    • April 2025 Corporate Deck
    • ASENT Annual Conf 2025
    • _Abstract
    • _Poster Presentation
    • _Slide Presentation
  • Investors
    • Press Releases
  • Contact
  • More
    • Home
    • ABOUT
      • Our Team
    • Science
      • Programs
      • Our Science
      • Publications
    • Events and Presentations
      • April 2025 Corporate Deck
      • ASENT Annual Conf 2025
      • _Abstract
      • _Poster Presentation
      • _Slide Presentation
    • Investors
      • Press Releases
    • Contact
  • Home
  • ABOUT
    • Our Team
  • Science
    • Programs
    • Our Science
    • Publications
  • Events and Presentations
    • April 2025 Corporate Deck
    • ASENT Annual Conf 2025
    • _Abstract
    • _Poster Presentation
    • _Slide Presentation
  • Investors
    • Press Releases
  • Contact
https://i.vimeocdn.com/video/2002744502-922c711c323d299e53c5cb405da73252d3d9c82df0c5b94e9d0ff8a1dae13ec8-d

Revolutionizing Cerebrovascular Repair

Revolutionizing Cerebrovascular Repair Revolutionizing Cerebrovascular Repair Revolutionizing Cerebrovascular Repair

Developing Novel Solutions for Neurotrauma and Neurodegeneration

#

STROKE

#

TRAUMATIC BRAIN INJURY

#

ALZHEIMER'S DISEASE

A New Class of Therapeutics

Stroke - PBS at Reperfusion

3D Visualization of neurovascular drop-out after experimental stroke in mice treated with saline (72 hours post-injury)

Stroke - LG3 at Reperfusion

3D Visualization of neurovascular protection of the same mice after treatment with LG3 (72 hours post-injury)

Publications

Internal Publications

Recombinant Human Perlecan DV and Its LG3 Subdomain Are Neuroprotective and Acutely Functionally Restorative in Severe Experimental Ischemic Stroke


External Publications

Perlecan Domain-V Enhances Neurogenic Brain Repair After Stroke in Mice


Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis


Epidermal Growth Factor and Perlecan Fragments Produced by Apoptotic Endothelial Cells Co-Ordinately Activate ERK1/2-Dependent Antiapoptotic Pathways in Mesenchymal Stem Cells


Perlecan Domain V Inhibits Amyloid-β Induced Brain Endothelial Cell Toxicity and Restores Angiogenic Function


Perlecan domain V inhibits alpha-2 integrin-mediated amyloid-beta neurotoxicity




Press Releases

Stream Biomedical, Inc., a privately held clinical-stage biopharmaceutical company, is dedicated to the development of first-in-class targeted therapeutics for the treatment of  acute neurotrauma and chronic neurodegenerative diseases of high unmet need.

March 04, 2025

Stream Biomedical, Inc. Announces Acceptance of Abstract for Presentation at Annual Meeting of the American Society of Neurotherapeutics (ASENT) Conference 2025 

Contact

Get in touch!

Stream Biomedical, Inc.

2450 Holcombe Boulevard, Suite J Houston, TX 77021

Send us a message

Attach Files
Attachments (0)

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Copyright © 2025 Stream Biomedical Inc. - All Rights Reserved.

  • Home
  • Programs
  • Contact

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept